DreaMed Diabetes (דרימד סוכרת)

Petah Tikva, Israel

DreaMed Diabetes is a medical device and SaaS company providing personalized diabetes treatment optimization solutions. The company, established as a spin-off of the DREAM International Consortium, commercializes the insulin control technology behind Glucositter, an artificial pancreas technology that was published in the New England Journal of Medicine. DreaMed Diabetes offers a clinically proven decision-support system for insulin titration in type-1 diabetes patients. Its Advisor Pro software was created by diabetes professionals and is based on real-world experience and artificial intelligence. Using it, any healthcare professional can analyze patient data in seconds and advise on the optimal treatment plan. With frequent titration changes and online monitoring, Advisor Pro enables better patient treatment, lowering their A1C levels and risk for complications. Using the Advisor Pro, physicians and nurses can provide true patient-centered care, and everyone can receive the same high-quality treatment. DreaMed Diabetes is working on decision-support tools in the diabetes management space and received a CE Mark and FDA clearance for a decision-support system using data from CGM/SMBG and insulin pumps.

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out DreaMed Diabetes (דרימד סוכרת) on @MedStartr Today #Diabetes #DiabetesManagement #Type1Diabetes #Type2Diabetes #MedicalDevices #MedMo #MedStartrVentures

https://www.medstartr.ai/s/FDf73jd9BxQ

Get Involved in DreaMed Diabetes (דרימד סוכרת)

🏢Is this your company? Claim This Profile

Join MedStartr to verify with your work email and edit this profile

Company Info

Founded: 2014
Website: dreamed.ai/

Disease Areas

Diabetes Diabetes Management Type 1 Diabetes Type 2 Diabetes

Technologies

SaaSMedical DevicesInsulin DeliveryAI/Machine Learning

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of DreaMed Diabetes (דרימד סוכרת)?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.